A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents

被引：2

作者：

Rizzo, Alessandro ^{[1
]}

Oderda, Marco ^{[2
]}

Mollica, Veronica ^{[1
]}

Merler, Sara ^{[3
]}

Morelli, Franco ^{[4
]}

Fragomeno, Benedetta ^{[1
]}

Taveri, Elena ^{[1
]}

Sorgentoni, Giulia ^{[5
]}

Santoni, Matteo ^{[5
]}

Massari, Francesco ^{[1
]}

机构：

[1] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[2] Univ Turin, San Giovanni Battista Hosp, Dept Urol, Citta Salute & Sci, Turin, Italy

[3] Azienda Osped Univ Integrata, Univ & Hosp Trust Verona, UOC Oncol, Verona, Italy

[4] IRCCS, Med Oncol Dept, Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy

[5] Macerata Hosp, Oncol Unit, Macerata, Italy

来源：

ANTI-CANCER DRUGS | 2022年 / 33卷 / 01期

关键词：

apalutamide; darolutamide; enzalutamide; nmCRPC; nonmetastatic; METASTASIS-FREE SURVIVAL; ENZALUTAMIDE; APALUTAMIDE; MEN; EVENTS;

D O I：

10.1097/CAD.0000000000001168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several novel androgen receptor (AR)-inhibitors have been introduced for nonmetastatic castration-resistant prostate cancer (nmCRPC) treatment, with the improvement of survival outcomes which need to be balanced against the risk of adverse events. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating enzalutamide, apalutamide and darolutamide in nmCRPC patients, to assess overall survival (OS), incidence and risk of adverse drug events, adverse-events-related death and adverse-events-related treatment discontinuation. We selected three RCTs (SPARTAN, PROSPER and ARAMIS). New hormonal agents administration resulted in better OS, despite the increased risk of several any grade and grade 3-4 adverse events. In the decision-making process, careful evaluation of expected adverse events, patients' comorbidities and maintenance of quality of life are mandatory.

引用

页码：E43 / E51

页数：9

共 50 条

[21] Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis
Rodriguez-Vida, Alejo
Rodriguez-Alonso, Andres
Useros-Rodriguez, Eduardo
Lopez-Campos, Fernando
Amor-Carro, Oscar
Arribas-Ruiz, Alberto
Martinez-Torres, Javier
Roca-Pardinas, Javier
Quesada-Garcia, Alba
Munoz-Del-Toro, Jacobo R.
Juarez-Soto, Alvaro
CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 197.e1 - 197.e10
[22] Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer
Smith, Matthew R.
Mehra, Maneesha
Nair, Sandhya
Lawson, Joe
Small, Eric J.
CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E180 - E189
[23] Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
Joshua, Anthony M.
Armstrong, Andrew
Crumbaker, Megan
Scher, Howard, I
de Bono, Johann
Tombal, Bertrand
Hussain, Maha
Sternberg, Cora N.
Gillessen, Silke
Carles, Joan
Fizazi, Karim
Lin, Ping
Duggan, William
Sugg, Jennifer
Russell, David
Beer, Tomasz M.
EUROPEAN JOURNAL OF CANCER, 2022, 170 : 285 - 295
[24] Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
Small, E. J.
Saad, F.
Chowdhury, S.
Oudard, S.
Hadaschik, B. A.
Graff, J. N.
Olmos, D.
Mainwaring, P. N.
Lee, J. Y.
Uemura, H.
De Porre, P.
Smith, A. A.
Zhang, K.
Lopez-Gitlitz, A.
Smith, M. R.
ANNALS OF ONCOLOGY, 2019, 30 (11) : 1813 - 1820
[25] Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
Rasmussen, Kelli M.
Patil, Vikas
Li, Chunyang
Yong, Christina
Appukkutan, Sreevalsa
Grossman, Jamie Partridge
Jhaveri, Jay
Halwani, Ahmad S.
JAMA NETWORK OPEN, 2023, 6 (10) : E2337272
[26] Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice
Lahcene, Halima
Aprikian, Armen G.
Vanhuyse, Marie
Hu, Jason
Bladou, Franck
Cury, Fabio
Kassouf, Wassim
Perreault, Sylvie
Dragomir, Alice
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 293 - 305
[27] Novel hormonal therapy for castration-resistant prostate cancer
Sternberg, C. N.
ANNALS OF ONCOLOGY, 2012, 23 : 259 - 263
[28] Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
Shore, Neal D.
Gratzke, Christian
Feyerabend, Susan
Werbrouck, Patrick
Carles, Joan
Vjaters, Egils
Tammela, Teuvo L. J.
Morris, David
Aragon-Ching, Jeanny B.
Concepcion, Raoul S.
Emmenegger, Urban
Fleshner, Neil
Grabbert, Markus
Lietuvietis, Vilnis
Mahammedi, Hakim
Cruz, Felipe M.
Paula, Adriano
Pieczonka, Christopher
Rannikko, Antti
Richardet, Martin
Silveira, Glauco
Kuss, Iris
Le Berre, Marie-Aude
Verholen, Frank
Sarapohja, Toni
Smith, Matthew R.
Fizazi, Karim
ONCOLOGIST, 2024, 29 (07) : 581 - 588
[29] A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer
Hird, Amanda E.
Magee, Diana E.
Bhindi, Bimal
Ye, Xiang Y.
Chandrasekar, Thenappan
Goldberg, Hanan
Klotz, Laurence
Fleshner, Neil
Satkunasivam, Raj
Klaassen, Zachary
Wallis, Christopher J. D.
CLINICAL GENITOURINARY CANCER, 2020, 18 (05) : 343 - 350
[30] Are Hormonal Agents Better Than Chemo in Metastatic Castration-resistant Prostate Cancer?
Yildirim, Serkan
Erdogan, Atike Pinar
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (03): : 350 - 354

← 1 2 3 4 5 →